



Medical Education on HPV

The activities at ICO



FX Bosch

ICO HPV RESEARCH PROGRAM
ICO / IARC HPV Information Centre
E-ONCOLOGIA PROGRAM



Potential conflict of interest

- Research and educational grants:
- GSK, SPMSD, Merck, Qiagen
- Personal grants travel and speaking: GSK, SPMSD, Merck, Qiagen, Hologic, Abbott, BD.



The HPV current program at ICO

- **Research**

- HPV typing in human cancer
- The HPV implication in head and neck cancers

- **Prevention**

- HPV vaccination trials
- HPV in screening
- Investigators initiated trials, the HPV FASTER consortium
- modeling

- **Education & Dissemination**

- HPV information centre
- HPV national reports
- HPV monograph program
- HPV TODAY
- e-learning in cervical cancer prevention
- e-learning in oncology






Resources available at ICO

Publications

e-learning/CX prevention

documentation



2500 hours
200 faculty
Intl program

Standard regional & country reports (192)

National integrated publication: Korea

THE ICO MONOGRAPH SERIES ON *HPV* AND CERVICAL CANCER


(2006-2008)



ICO: Institut Català d'Oncologia www.iconcologia.net hpvcentre@iconcologia.net


2006

Vol 24, Suppl 3



2007

Vol 25, Suppl 3



2008

Vol 26, Suppl 10



Vol 26, Suppl 11

Latin America and Caribbean
Regional Report



SPANISH*



Vol 26, Suppl 12

Asia Pacific
Regional Report



JAPANESE*

CHINESE*



A critical systematic review of the international literature • A targeted series of regional reports • A user-friendly distant-learning platform
www.e-oncologia.org

Ordering Information


www.elsevier.com/locate/vaccine

- One guest editor
- 8/12 editors. 50/60 chapter leaders
- 184 invited authors international/regional
- Over 200 reviewers;
- Over +100 Institutions
- 6 editorial & 2 peer review meetings
- Over 200.000 copies distributed
- Over 60 000 free downloads


* Include the General Overview and the Regional Report

ICO HPV Monograph Series


Most recent publications (2012-2013)



Vol 30, Suppl 4




Vol 30, Suppl 5




2012


Vol 31, Suppl 5




Vol 31, Suppl 7




Vol 31, Suppl 6



Vol 31, Suppl 8



2013




* Russian
* French



Possible areas of collaboration:

PVR to sponsor meetings and publications on specific topics of public health interest
Official journal of the IPV society

INTERNATIONAL CERVICAL CANCER PREVENTION COURSE



Credits and scientific endorsements

- ✓ Scientific editors: Mireia Díaz, Silvia de Sanjosé, Xavier Castellsagué, R. Sankaranarayanan, Laia Bruni, Laia Alemany, Maria Brotons, F. Xavier Bosch
- ✓ Course reviewers: J Cuzick, R. Sankaranarayanan; J Paavonen
- ✓ Participant Institutions:



**International
Federation of
Gynecology and
Obstetrics**



**International
Atomic Energy
Agency**



**Union for
International
Cancer Control**



**International
Agency
for research in
cancer**



**WHO/ICO
Information Centre
on HPV and
Cervical Cancer**



Elsevier



With the participation of the World Health Organization

Accreditation



Accreditation
Council of
Oncology in
Europe



Spain accreditation



SEAFORMEC
Sistema Español de Acreditación
de la Formación Médica Continuada



Morocco accreditation

ASSOCIATION
LALLA SALMA
DE LUTTE CONTRE
LE CANCER



Local universities and professional associations:

Girona, Salamanca, Ghana, Tanzania, Uganda, Zambia and other.



American Medical Association (AMA) 1 credit per hour of activity

Course structure

Additional sources of information

- A library of frequently asked questions (FAQs).
- Access to the ICO HPV Monograph Series (Vaccine 2006, 2007 and 2008 a,b,c).



- Other major educational resources and documents.

Tutorship

Participant's forum supported by international tutors and e-oncología.

18 hours Core Contents



Accreditation


Accredited by the “**Commission for Continuing Education of Spanish National Health System**” with 3,2 credits and by the “**Accreditation Council of Oncology in Europe (ACOE)**” with 15 credits.

Successful participants will receive a FIGO accreditation and diploma.


Evaluation

- A 30 multiple-choice questionnaire.
- An evaluation of participation in the virtual forums.

Course specific adaptations and creating new contents



Model deployment – training in cascade, empowering tutors and free access




Представление Ключевые положения Основная часть Заключение


報告	關鍵訊息	內容	總結
----	------	----	----

● 防卫和免疫原性
防卫机制

- 接种疫苗能诱导 **血清抗体** 的产生。
- 通过 **渗透作用** 疫苗诱导抗体在注射部位表达
- **高水平的** 血清抗体诱导感染部位 **更高水平** 的抗体产生。
- 更高的抗体水平，意味着在接种后能获得更**长久**的保护。
- 抗体能 **中和** 病毒并 **防止** 其进入细胞。



Global Results Overview. Participants geographical distribution 2011-2014




+ 12.000 participants in 50 months

Outcome January 2015

Language	Participants	% success
SPANISH	10681	70
ENGLISH	557	60
FRENCH	268	62
RUSSIAN	48	69
TOTAL	11554	69

Satisfaction survey results II



Financial supports and sponsorship of the course

Bill & Melinda Gates Fund. Grant to support the WHO / ICO HPV information centre & the ICO Monograph program.



BILL & MELINDA
GATES foundation

International Educational Program in Oncology of the ICO (Barcelona, Spain).



 Generalitat de Catalunya
Departament de Salut



IAEA contract to e-oncologia to pilot the course of VUCCnet in Tanzania, Zambia, Ghana & Nigeria. Sub-project in partnership with Universities in Egypt and South Africa



[Building partnerships to fight the cancer epidemic](#)

IS GLOBAL (Barcelona, Spain) through a cooperation agreement financed by "La Caixa" Foundation.

ISGlobal



Ministry of Health in collaboration with the Lalla Salma Association to Fight against Cancer in the National Cancer Plan



Unrestricted educational grant from Glaxo Smith Klein (GSK).



Unrestricted educational grant from Merck Sharp & Dohme Corporation.



Areas of collaboration

- Support the free access and language extension
 - Direct sponsorship
 - Disseminate information and identify collaborators
- Create / recommend novel modules (offered to 15,000 participants in the network)






ICO / IARC HPV information Centre



WHAT IS THE ICO INFORMATION CENTRE ON HPV AND CANCER?





Human Papillomavirus and Related Diseases Report


BELARUS

Version posted on www.hpvcentre.net in March 20th, 2015

- **CONCEPT:** Is an international Centre that compiles, analyzes, synthesizes and disseminates country-specific information related to HPV, cervical cancer and other relevant HPV-related indicators.
- **AIM:** To facilitate global, regional- and country-specific decisions on current and novel options for the prevention of cervical cancer, specially HPV vaccination.
- **Information is presented at:**
 - the global World level
 - for 5 continents, and
 - for each of the 193 WHO member countries








Statistics are summarized and displayed through tables, several figures (forest plots, bar charts, line charts, maps). Main products comprise full reports, abridged reports and a queryable database.

Visits per month
ICO Information Centre on HPV and Cancer
www.hpvcentre.net



Info center Publications (examples)



- Worldwide prevalence of HPV by region / country
- Worldwide HPV vaccination coverage by birth cohort

Next steps: Information Centre 2.0



- Progress towards a dynamic high-tech website:
 - Dynamic updating (as opposed to massive and slow updates)
 - Work on new indicators: cost-effectiveness and vaccine effectiveness
 - Develop cutting edge technology for quasi-automatic data extraction, processing and display
 - Improve data visualization and interactive online tools: knowledge navigator
- To increase visibility using new technologies
- Expansion to general population users:
 - media surveillance of public needs, demands, concerns and potential health alarms of HPV-related issues in the general population using web 2.0 techniques
 - Provide customized feedback according to needs and alarms
- Consolidate the visiting scientist program

Potential for collaboration



- PVR monographic supplements
 - Specific issues of HPV TODAY
- Sponsoring participation to regional meetings
 - Gynecology
 - Pediatricians
- Additional modules to the e-learning program
- Country specific reports



Thank you



Join this worldwide international effort



Thank you

x.bosch@iconcologia.net

Coverage of the last reported vaccinated cohort



Programs' primary targets are girls aged 10-14. Target age varies by country, but commonly is 12 years olds

* Finland: reported one dose coverage only

Data Source: Laia Bruni, personal communication. Work submitted
Updated November 2015